We Are Beating Multiple Myeloma Now. Join Us.

Multiple myeloma patients have options today because the status quo just a few years ago was, to us, unacceptable.

The model we have created for drug discovery and development is revolutionary. It brings multiple myeloma treatments to trial 60% faster than average. It has resulted in six multiple myeloma drugs receiving FDA approval in the time it normally takes for one. Through the power of new technology, genomics and immunology, it has extended lives that would have been lost to multiple myeloma yesterday. And it is accelerating all the time. Learn how we are doing it.

To improve the outcome, we partnered withthe best and rewrote the rules.

2014

Plan to open 10 new trials

2014

CoMMpass Study enrollment almost completed

2014

MMRC launches50th clinical trial

2013

CoMMunity and Researcher Gateways launched

2013

Pomylast® approved

2012

Krypolis® approved

2011

Record 8 treatments inPhase III trials

2011

MMRF CoMMpassSM launched

2008

Doxil approved

2007

Revlimid® approved

2006

Thalomid® approved

2004

MMRC tissue bank established

2004

MMRC founded

2003

Velcade® approved

2002

Zometa® approved

1998

MMRF established

The MMRF changed the multiple myeloma treatmentlandscape by removing obstacles and injecting speed at each step ofthe research and drug development process.

If you have multiple myeloma,you have options.

At the MMRF, we’re urgently working to develop treatments to extend your life. We can notify you about clinical trials, connect you to other patients with the same disease characteristics, bring you the latest breaking developments, and more. We’re learning every day. You can too.